BioAdvance News

Immunome Antibody Cocktail (IMM-BCP-01) Neutralizes the SARS-CoV-2 Delta Variant in Pre-clinical Testing

By WebmasterJuly 20, 2021November 1st, 2024No Comments

Immunome Antibody Cocktail (IMM-BCP-01) Neutralizes the SARS-CoV-2 Delta Variant in Pre-clinical Testing

– IMM-BCP-01 already shown to neutralize all other CDC variants of concern in pre-clinical testing

– IND submission planned for this quarter

Previous PostRide Health and the American Heart Association Partner to Improve Health Equity for Patients Facing Transportation Barriers
Next PostCrossBridge Health acquires Geisinger-developed PACER software